186 related articles for article (PubMed ID: 36763285)
1. Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study.
Pilgram L; Appel KS; Ruethrich MM; Koll CEM; Vehreschild MJGT; de Miranda SMN; Hower M; Hellwig K; Hanses F; Wille K; Haselberger M; Spinner CD; Vom Dahl J; Hertenstein B; Westhoff T; Vehreschild JJ; Jensen BO; Stecher M
Infection; 2023 Aug; 51(4):1033-1049. PubMed ID: 36763285
[TBL] [Abstract][Full Text] [Related]
2. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study.
Spagnuolo V; Voarino M; Tonelli M; Galli L; Poli A; Bruzzesi E; Racca S; Clementi N; Oltolini C; Tresoldi M; Rovere Querini P; Dagna L; Zangrillo A; Ciceri F; Clementi M; Castagna A;
Drug Des Devel Ther; 2022; 16():3645-3654. PubMed ID: 36268521
[TBL] [Abstract][Full Text] [Related]
3. First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)".
Jakob CEM; Borgmann S; Duygu F; Behrends U; Hower M; Merle U; Friedrichs A; Tometten L; Hanses F; Jung N; Rieg S; Wille K; Grüner B; Klinker H; Gersbacher-Runge N; Hellwig K; Eberwein L; Dolff S; Rauschning D; von Bergwelt-Baildon M; Lanznaster J; Strauß R; Trauth J; de With K; Ruethrich M; Lueck C; Nattermann J; Tscharntke L; Pilgram L; Fuhrmann S; Classen A; Stecher M; Schons M; Spinner C; Vehreschild JJ
Infection; 2021 Feb; 49(1):63-73. PubMed ID: 33001409
[TBL] [Abstract][Full Text] [Related]
4. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
5. Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir.
Santos Bravo M; Alonso R; Soria D; Sánchez Palomino S; Sanzo Machuca Á; Rodríguez C; Alcamí J; Díez-Fuertes F; Simarro Redon À; Hurtado JC; Fernández Avilés F; Bodro M; Rubio E; Villanueva JL; Vergara A; Castro P; Tuset M; Cuesta G; Puerta P; García C; Mosquera Gutiérrez MDM; Martínez MJ; Vila J; Soriano A; Marcos MÁ
Microbiol Spectr; 2022 Dec; 10(6):e0244822. PubMed ID: 36354320
[TBL] [Abstract][Full Text] [Related]
6. Study of Efficacy of Injection Remdesivir in Patients of COVID-19.
Chaudhary BR; Dudhrejia PJ; Gambhir RM; Rathod MM
J Assoc Physicians India; 2023 Apr; 71(4):11-12. PubMed ID: 37355792
[TBL] [Abstract][Full Text] [Related]
7. Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study.
Garibaldi BT; Wang K; Robinson ML; Betz J; Caleb Alexander G; Andersen KM; Joseph CS; Mehta HB; Korwek K; Sands KE; Fisher AM; Bollinger RC; Xu Y
Clin Infect Dis; 2022 Aug; 75(1):e516-e524. PubMed ID: 34910128
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort.
Mozaffari E; Chandak A; Zhang Z; Liang S; Thrun M; Gottlieb RL; Kuritzkes DR; Sax PE; Wohl DA; Casciano R; Hodgkins P; Haubrich R
Clin Infect Dis; 2022 Aug; 75(1):e450-e458. PubMed ID: 34596223
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir and Mortality in Patients With Coronavirus Disease 2019.
Diaz GA; Christensen AB; Pusch T; Goulet D; Chang SC; Grunkemeier GL; McKelvey PA; Robicsek A; French T; Parsons GT; Doherty G; Laurenson C; Roper R; Hadlock J; Cover CJ; Footer B; Robinson P; Micikas M; Marfori JE; Cronenweth C; Mukkamala Y; Mackiewicz J; Rai E; Matson MD; Davila J; Rueda J; Tipton R; Algren H; Ward BC; Malkoski S; Gluckman T; Tallman GB; Arguinchona H; Hammond TC; Standaert S; Christensen J; Echaiz JF; Choi R; McClung D; Pacifico A; Fee M; Sarafian F; Berrington WR; Goldman JD
Clin Infect Dis; 2022 May; 74(10):1812-1820. PubMed ID: 34409431
[TBL] [Abstract][Full Text] [Related]
10. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
[TBL] [Abstract][Full Text] [Related]
11. Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19.
Chakraborty A; Diwan A; Chiniga V; Arora V; Holkar P; Thakur Y; Tatake J; Barton R; Holkar N; Pandey R; Pond B
PLoS One; 2022; 17(12):e0278963. PubMed ID: 36584166
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment.
Polivka L; Gajdacsi J; Fazekas L; Sebok S; Barczi E; Hidvegi E; Sutto Z; Dinya E; Maurovich-Horvat P; Szabo AJ; Merkely B; Müller V
J Glob Health; 2022 Aug; 12():05031. PubMed ID: 36040909
[TBL] [Abstract][Full Text] [Related]
13. Compassionate use of remdesivir in children with COVID-19.
Méndez-Echevarría A; Pérez-Martínez A; Gonzalez Del Valle L; Ara MF; Melendo S; Ruiz de Valbuena M; Vazquez-Martinez JL; Morales-Martínez A; Remesal A; Sándor-Bajusz KA; Cabañas F; Calvo C
Eur J Pediatr; 2021 Apr; 180(4):1317-1322. PubMed ID: 33200304
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
16. An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).
Pagliano P; Sellitto C; Scarpati G; Ascione T; Conti V; Franci G; Piazza O; Filippelli A
Expert Opin Drug Discov; 2022 Jan; 17(1):9-18. PubMed ID: 34412564
[TBL] [Abstract][Full Text] [Related]
17. Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection.
Pitts J; Babusis D; Vermillion MS; Subramanian R; Barrett K; Lye D; Ma B; Zhao X; Riola N; Xie X; Kajon A; Lu X; Bannister R; Shi PY; Toteva M; Porter DP; Smith BJ; Cihlar T; Mackman R; Bilello JP
Antiviral Res; 2022 Jul; 203():105329. PubMed ID: 35525335
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type.
Mohammad A; Al-Mulla F; Wei DQ; Abubaker J
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34206274
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.
Olender SA; Perez KK; Go AS; Balani B; Price-Haywood EG; Shah NS; Wang S; Walunas TL; Swaminathan S; Slim J; Chin B; De Wit S; Ali SM; Soriano Viladomiu A; Robinson P; Gottlieb RL; Tsang TYO; Lee IH; Hu H; Haubrich RH; Chokkalingam AP; Lin L; Zhong L; Bekele BN; Mera-Giler R; Phulpin C; Edgar H; Gallant J; Diaz-Cuervo H; Smith LE; Osinusi AO; Brainard DM; Bernardino JI;
Clin Infect Dis; 2021 Dec; 73(11):e4166-e4174. PubMed ID: 32706859
[TBL] [Abstract][Full Text] [Related]
20. Use of Remdesivir in children with COVID-19: report of an Italian multicenter study.
Romani L; Roversi M; Bernardi S; Venturini E; Garazzino S; Donà D; Krzysztofiak A; Montagnani C; Funiciello E; Calò Carducci FI; Marabotto C; Castagnola E; Salvini F; Lancella L; Lo Vecchio A; Galli L; Castelli Gattinara G;
Ital J Pediatr; 2024 Feb; 50(1):32. PubMed ID: 38413992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
